Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Altered supernormality in multiple sclerosis peripheral nerve.

A Eisen, D Paty, M Hoirch

    Muscle & Nerve
    |May 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Breast cancer diagnosis and treatment wait times in specialized diagnostic units compared with usual care: a population-based study.

    Current oncology (Toronto, Ont.)·2020
    Same author

    Baseline staging imaging for distant metastasis in women with stages I, II, and III breast cancer.

    Current oncology (Toronto, Ont.)·2020
    Same author

    Cost-utility analysis of 21-gene assay for node-positive early breast cancer.

    Current oncology (Toronto, Ont.)·2019
    Same author

    Impact of a novel prioritization framework on clinician-led oncology drug submissions.

    Current oncology (Toronto, Ont.)·2019
    Same author

    Response to: The Survival Time of 8376 Male Breast Cancer Patients.

    Clinical oncology (Royal College of Radiologists (Great Britain))·2018
    Same journal

    Late-Onset Myasthenia Gravis: An Increasingly Frequent Clinical Entity With Distinctive Challenges.

    Muscle & nerve·2026
    Same journal

    Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature.

    Muscle & nerve·2026
    Same journal

    Muscle-Specific Kinase Signaling and Its Therapeutic Potential.

    Muscle & nerve·2026
    Same journal

    Optimization of the Cell-Based Assay Methodology to Study Degradation of Acetylcholine Receptors (Antigenic Modulation) by Antibodies From Myasthenia Gravis Patients.

    Muscle & nerve·2026
    Same journal

    Review of Congenital Myasthenic Syndrome Caused by Pathogenic Variants in GFPT1.

    Muscle & nerve·2026
    Same journal

    Accuracy of Palpation-Guided Versus First Attempt at Ultrasound-Guided Electromyography Needle Placement for the Extensor Carpi Radialis Longus and Brevis by Trainees.

    Muscle & nerve·2026
    See all related articles

    Supernormality, a nerve recovery phenomenon, was impaired in 42.5% of multiple sclerosis patients. This suggests peripheral nervous system involvement in MS, impacting nerve function recovery.

    Area of Science:

    • Neuroscience
    • Clinical Electrophysiology

    Background:

    • Nerve recovery cycles include a phase called supernormality.
    • Supernormality is typically measured by the amplitude ratio of nerve action potentials following conditioning and test stimuli.

    Purpose of the Study:

    • To investigate the presence and significance of supernormality in patients with multiple sclerosis (MS).
    • To determine if impaired supernormality indicates peripheral nervous system involvement in MS.

    Main Methods:

    • Median sensory nerve action potential amplitude was recorded at the elbow in control subjects and MS patients.
    • A supramaximal conditioning shock was applied 6 ms before the test pulse to assess supernormality (S2 conditioned/S2 unconditioned ratio).

    Main Results:

    Related Experiment Videos

    • Control subjects exhibited a mean supernormality ratio of 285 +/- 174.
    • 42.5% of multiple sclerosis patients (17 out of 40) failed to demonstrate supernormality, with ratios below 100.

    Conclusions:

    • Impaired supernormality in multiple sclerosis patients likely indicates a delay in the nerve recovery cycle.
    • This finding provides further evidence for peripheral nervous system dysfunction in MS.